Loading
Imetelstat is a lipid-linked oligonucleotide that binds the RNA template of telomerase, the enzyme cancer cells use to stay immortal, and it is the first telomerase inhibitor approved for any cancer. In lower-risk myelodysplastic syndromes it freed 40% of transfusion-dependent patients from transfusions for at least eight weeks versus 15% on placebo, once growth factors have failed.
Imetelstat is a 13-mer lipid-conjugated oligonucleotide that binds the RNA template of telomerase (hTR), inhibiting the enzyme in malignant clones that depend on high telomerase activity; it is the first telomerase inhibitor approved for any cancer. In the IMerge phase 3 trial (2024), 40% of patients with lower-risk transfusion-dependent myelodysplastic syndromes achieved 8-week transfusion independence versus 15% with placebo and reductions in mutant allele burden suggested disease modification. It was approved in the US in 2024 for low- to intermediate-1-risk MDS with transfusion-dependent anaemia after erythropoiesis-stimulating agents fail, and in the EU in 2025. The IMpactMF phase 3 trial in JAK-inhibitor-refractory myelofibrosis tests whether it extends overall survival. For a newcomer: a drug that attacks the enzyme cancer cells use to stay immortal.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
13-mer lipid-conjugated oligonucleotide that binds the RNA template of telomerase (hTR), inhibiting telomerase in malignant clones with high telomerase activity.
1.Imetelstat slips into a pocket on its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Every-four-week infusion for lower-risk MDS (approved June 2024).
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. Transfusion-dependent lower-risk MDS after ESA failure.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: imetelstat. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2024 | Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure |
| EU | 2025 | Lower-risk MDS transfusion-dependent anaemia |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
IMerge validated telomerase as a drug target in cancer, decades after its discovery, and gave a second-line option for MDS patients whose anaemia no longer responds to erythropoietin or luspatercept. The hint of clonal reduction is what makes the drug interesting beyond transfusion counts. Cytopenias require close monitoring in the first cycles.
COMMANDS moved luspatercept from second line (after ESA failure, MEDALIST trial) to first line, offering transfusion-dependent lower-risk MDS patients a better chance of transfusion freedom from the start. It changed guidelines and labels in 2023. Erythropoietin remains a reasonable and cheaper option for patients without ring sideroblasts or with low transfusion burden.
Query for this drug: (TITLE:"Imetelstat" OR ABSTRACT:"Imetelstat" OR TITLE:"Rytelo" OR ABSTRACT:"Rytelo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Imetelstat, not a curated reading list.
Shares IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed, COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions, Anaemia, SF3B1 mutation.
Shares IMerge, COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions, Myelodysplastic syndromes / neoplasms (MDS).
Shares Lower-risk myelodysplastic syndromes, Primary myelofibrosis, Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Lower-risk myelodysplastic syndromes, Transfusion support and anaemia management, Myelodysplastic syndromes / neoplasms (MDS).
Shares Transfusion support and anaemia management, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Lower-risk myelodysplastic syndromes, Transfusion support and anaemia management, Myelodysplastic syndromes / neoplasms (MDS).
Shares Transfusion support and anaemia management, Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Lower-risk myelodysplastic syndromes, Transfusion support and anaemia management, Primary myelofibrosis.